NCT01251718已完成不适用
Post-marketing Surveillance of Donepezil Hydrochloride- Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 894
- 主要终点
- ADAS-Jcog (test of cognitive function)
研究概览
简要总结
To investigate the clinical safety and effectiveness of donepezil hydrochloride administration in patients with mild or moderate Alzheimer's Disease
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Donepezil Hydrochloride
干预措施: donepezil hydrochloride (Drug)
结局指标
主要结局
ADAS-Jcog (test of cognitive function)
时间窗: 36 month (12 weeks and every 6 months)
次要结局
- Adverse events/adverse drug reactions(36 months)
研究者
相似试验
已完成
不适用
Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's DiseaseAlzheimer's DeseaseNCT02162251Eisai Co., Ltd.3,482
已完成
不适用
Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).Dementia With Lewy Body DiseaseNCT02448784Eisai Co., Ltd.591
未知
Unknown
Post-marketing surveillance of donepezil hydrochloride -Investigation of the clinical safety and effectiveness in patients with Alzheimer's DiseaseAlzheimer's DiseaseJPRN-jRCT1080221997Eisai Co., Ltd.1,000
未知
Unknown
Post-marketing surveillance of donepezil hydrochloride Dementia with Lewy bodies/long-term administratioDementia with Lewy bodiesJPRN-jRCT1080222854Eisai Co., Ltd.500
未知
Unknown
Investigation of the safety and effectiveness of combination therapy of donepezil hydrochloride and memantine hydrochloride in patients with Alzheimer's DiseaseAlzheimer's DiseaseJPRN-jRCT1080222139Eisai Co., Ltd.5,000